![logo](/logos/EGRX.webp)
Eagle Pharmaceuticals, Inc.
NASDAQ:EGRX
4.25 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Eagle Pharmaceuticals, Inc. |
Symbool | EGRX |
Munteenheid | USD |
Prijs | 4.25 |
Beurswaarde | 55,194,750 |
Dividendpercentage | 0% |
52-weken bereik | 3.21 - 17.32 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Scott L. Tarriff |
Website | https://www.eagleus.com |
An error occurred while fetching data.
Over Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)